{"title":"美国食品和药物管理局批准第 100 种单克隆抗体产品","authors":"Asher Mullard","doi":"10.1038/d41573-021-00079-7","DOIUrl":null,"url":null,"abstract":"Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year. Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"20 7","pages":"491-495"},"PeriodicalIF":91.2000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"228","resultStr":"{\"title\":\"FDA approves 100th monoclonal antibody product\",\"authors\":\"Asher Mullard\",\"doi\":\"10.1038/d41573-021-00079-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year. Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year.\",\"PeriodicalId\":19068,\"journal\":{\"name\":\"Nature Reviews. Drug Discovery\",\"volume\":\"20 7\",\"pages\":\"491-495\"},\"PeriodicalIF\":91.2000,\"publicationDate\":\"2021-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"228\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews. Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-021-00079-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-021-00079-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year. Thirty-five years on from the FDA’s approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency’s new drug approvals each year.
期刊介绍：
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena.
Each issue includes:
Highest-quality reviews and perspectives covering a broad scope.
News stories investigating the hottest topics in drug discovery.
Timely summaries of key primary research papers.
Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
